Sfoglia per AUTORE
LELEU X
Collezione AOU Città della Salute di Torino

  

Items : 23

2024
AOU Città della Salute di Torino

Rodriguez-Otero P; Usmani S; Cohen AD; van de Donk NWCJ; Leleu X; Gállego Pérez-Larraya J; Manier S; Nooka AK; Mateos MV; Einsele H; Minnema M; Cavo M; Derman BA; Puig N; Gay F; Ho PJ; Chng WJ; Kastritis E; Gahrton G; Weisel K; Nagarajan C; Schjesvold F; Mikhael J; Costa L; Raje NS; Zamagni E; Hájek R; Weinhold N; Yong K; et alii...

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma. in Haematologica / Haematologica. 2024 Jul 1;109(7):2337-2340. doi: 10.3324/haematol.2023.284694.
2024
AOU Città della Salute di Torino

Mateos MV; Weisel K; Terpos E; Delimpasi S; Kastritis E; Zamagni E; Delforge M; Ocio E; Katodritou E; Gay F; Larocca A; Leleu X; Otero PR; Schjesvold F; Cavo M; Dimopoulos MA;

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. in The New England journal of medicine / N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
2024
AOU Città della Salute di Torino

Moreau P; Bladé J; Rodriguez-Otero P; Carson R; de Boer CJ; Sitthi-Amorn A; Vanquickelberghe V; van Brummelen EMJ; Vieyra D; Wang J; Liu Y; Ahmadi T; Lonergan S; Jurczyszyn A; Hajek R; Spencer A; Einsele H; Vangsted A; Silzle T; Roeloffzen W; Delforge M; Rosiñol L; Sureda Balari A; Schjesvold F; Katodritou E; van de Donk NWCJ; Nijhof IS; Mina R; Gay F; et alii...

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma. in Future oncology (London, England) / Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17.
2024
AOU Città della Salute di Torino

Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; van de Donk NWCJ; Katodritou E; Schjesvold F; Balari AS; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; et alii...

Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. in British journal of haematology / Br J Haematol. 2022 Feb;196(3):639-648. doi: 10.1111/bjh.17887. Epub 2021 Oct 21.
2022
AOU Città della Salute di Torino

Laubach J; Nadeem O; Mazumder A; Raptis A; Rodriguez-Otero P; Oriol A; Alegre A; Cavo M; Maisel C; Mateos MV; Paner A; Bladé J; Touzeau C; Leleu X; Larocca A; Sandberg A; Orre M; Torrång A; Bakker NA; Richardson PG;

Melphalan flufenamide for relapsed/refractory multiple myeloma. in Drugs of today (Barcelona, Spain : 1998) / Drugs Today (Barc). 2022 Aug;58(8):407-423. doi: 10.1358/dot.2022.58.8.3367680.
2022
AOU Città della Salute di Torino

Nadeem O; Mateos MV; Efebera YA; Paner A; Larocca A; Rodríguez-Otero P; Leleu X; Richardson PG;

2021
AOU Città della Salute di Torino

Zonder J; Boccadoro M; Thompson M; Weisel K; Berdeja J; Lee HC; Leleu X; Huang H; Stull DM; Cherepanov D; Terpos E; Hajek R; Romanus D; Palumbo A; Abonour R; Usmani S; Morgan G; Costello C; Rifkin R; Davies F; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A;

Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. in American journal of hematology / Am J Hematol. 2021 Nov 1;96(11):E423-E427. doi: 10.1002/ajh.26319. Epub 2021 Sep 23.
2021
AOU Città della Salute di Torino

Schjesvold F; Bringhen S; G Richardson P; Perrot A; Leleu X; Moreau P; A Dimopoulos M; Hulin C; Tekle C; Foster MC; Poole EM; van de Velde H; Facon T;

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Mar 1;39(7):757-767. doi: 10.1200/JCO.20.02259. Epub 2020 Dec 9.
2021
AOU Città della Salute di Torino

Laubach JP; Moreb JS; Anderson KC; Raptis A; Mazumder A; Maisel C; Paner A; Alegre A; Hassoun H; Touzeau C; Hiemenz JW; Nadeem O; Leleu X; Rodriguez-Otero P; Cavo M; Bladé J; Larocca A; Oriol A; Richardson PG; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. in The Lancet. Oncology / Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.
2021
AOU Città della Salute di Torino

Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; et alii...

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. in Leukemia / Leukemia. 2021 Jan;35(1):31-44. doi: 10.1038/s41375-020-01016-0. Epub 2020 Aug 19.
2021
AOU Città della Salute di Torino

van de Donk N; Leleu X; Engelhardt M; Garderet L; Jackson G; Weisel K; Caers J; Delforge M; Mateos MV; Einsele H; Mohty M; Zojer N; Terpos E; Avet-Loiseau H; Gay F; Dimopoulos MA; Hajek R; Facon T; Driessen C; Zweegman S; Pawlyn C; San-Miguel J; Cavo M; Moreau P; Boccadoro M; Ludwig H; Goldschmidt H; Beksac M; Nijhof I; et alii...

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. in The Lancet. Haematology / Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.
2021
AOU Città della Salute di Torino

Ludwig H; Sonneveld P; Facon T; San-Miguel J; Avet-Loiseau H; Mohty M; Mateos MV; Moreau P; Cavo M; Pawlyn C; Zweegman S; Engelhardt M; Driessen C; Cook G; Dimopoulos MA; Gay F; Einsele H; Delforge M; Caers J; Weisel K; Jackson G; Garderet L; van de Donk N; Leleu X; Goldschmidt H; Beksac M; Nijhof I; Schreder M; Abildgaard N; et alii...

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. in British journal of haematology / Br J Haematol. 2021 Aug;194(3):496-507. doi: 10.1111/bjh.17338. Epub 2021 Mar 16.
2021
AOU Città della Salute di Torino

Sezer O; Sonneveld P; Reece D; Rasche L; Moreau P; Mohty M; Merlini G; Lentzsch S; Mateos MV; Leleu X; Leal da Costa F; Kyle RA; Kröger N; Jurczyszyn A; Hungria V; Hájek R; Gay F; Gahrton G; Fernández de Larrea C; Engelhardt M; Dispenzieri A; Einsele H; Dimopoulos MA; Cavo M; Caers J; Badros A; Anderson KC; Van de Donk NWCJ; Zamagni E; et alii...

Melflufen for relapsed and refractory multiple myeloma. in Expert opinion on investigational drugs / Expert Opin Investig Drugs. 2020 Oct;29(10):1069-1078. doi: 10.1080/13543784.2020.1808884. Epub 2020
2020
AOU Città della Salute di Torino

Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG;

2020
AOU Città della Salute di Torino

Jantunen E; Cahn JY; Itälä-Remes M; Vandenberghe E; Özkurt ZN; Crysandt M; Poiré X; Anagnostopoulos A; Leleu X; Janikova A; de Villambrosia SG; Bishton M; Bruno B; Snowden JA; Gritti G; Bittenbring JT; Finel H; Michieli MG; Masszi T; Trn?ný M; Blaise D; Boumendil A; González-Barca E; Schroyens W; Maertens J; Esquirol A; Dreger P; Montoto S; Sureda A; et alii...

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2020 Dec 1;38(34):4030-4041. doi: 10.1200/JCO.20.02060. Epub 2020 Oct 6.
2020
AOU Città della Salute di Torino

Labotka R; Vorog A; Morgan G; Mateos MV; Iida S; Leleu X; Katodritou E; Chng WJ; Beksac M; Bringhen S; Garg M; Hájek R; Oriol A; Quach H; Špi?ka I; Dimopoulos MA; Wang B; Palumbo A; Lonial S;

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. in JAMA oncology / JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.
2018
AOU Città della Salute di Torino

Gay F; Jackson G; Rosiñol L; Holstein SA; Moreau P; Spada S; Davies F; Lahuerta JJ; Leleu X; Bringhen S; Evangelista A; Hulin C; Panzani U; Cairns DA; Di Raimondo F; Macro M; Liberati AM; Pawlyn C; Offidani M; Spencer A; Hájek R; Terpos E; Morgan GJ; Bladé J; Sonneveld P; San-Miguel J; McCarthy PL; Ludwig H; Boccadoro M; et alii...

Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate? in Annals of hematology / Ann Hematol. 2018 Mar;97(3):387-400. doi: 10.1007/s00277-017-3191-7. Epub 2017 Dec 27.
2018
AOU Città della Salute di Torino

Allcott K; Flament A; Gay F; Leleu X; Delforge M;

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. in Leukemia / Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2.
2018
AOU Città della Salute di Torino

Beksac M; Waage A; van de Donk NWCJ; Weisel K; Kaiser M; Jackson G; Goldschmidt H; Leleu X; Cook G; Mateos MV; Garderet L; Zweegman S; Terpos E; San-Miguel JF; Dimopoulos MA; Cavo M; Mohty M; Hajek R; Boccadoro M; Avet-Loiseau H; Moreau P; Gay F; Einsele H; Facon T; Delforge M; Ludwig H; Mellqvist UH; Engelhardt M; Caers J; et alii...

2017
AOU Città della Salute di Torino

Ludwig H; Delforge M; Facon T; Einsele H; Gay F; Moreau P; Avet-Loiseau H; Boccadoro M; Hajek R; Mohty M; Cavo M; Dimopoulos MA; San-Miguel JF; Terpos E; Zweegman S; Garderet L; Mateos MV; Cook G; Leleu X; Goldschmidt H; Jackson G; Kaiser M; Weisel K; van de Donk NWCJ; Waage A; Beksac M; Mellqvist UH; Engelhardt M; Caers J; et alii...

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. in The oncologist / Oncologist. 2016 Mar;21(3):333-42. doi: 10.1634/theoncologist.2015-0303. Epub 2016 Feb 26.
2016
AOU Città della Salute di Torino

Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M;

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. in The Lancet. Haematology / Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18.
2016
AOU Città della Salute di Torino

Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C;

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. in The Lancet. Oncology / Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
2014
AOU Città della Salute di Torino

Rajkumar SV; Dimopoulos MA; Palumbo A; Blade J; Merlini G; Mateos MV; Kumar S; Hillengass J; Kastritis E; Richardson P; Landgren O; Paiva B; Dispenzieri A; Weiss B; LeLeu X; Zweegman S; Lonial S; Rosinol L; Zamagni E; Jagannath S; Sezer O; Kristinsson SY; Caers J; Usmani SZ; Lahuerta JJ; Johnsen HE; Beksac M; Cavo M; Goldschmidt H; et alii...